{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:53:06Z","timestamp":1789105986539,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU23\\u201303-00188"],"award-info":[{"award-number":["NU23\\u201303-00188"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jconrel.2025.113876","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T19:38:36Z","timestamp":1747856316000},"page":"113876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas"],"prefix":"10.1016","volume":"384","author":[{"given":"Ond\u0159ej","family":"Lidick\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Rene\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Kudl\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Filipov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"B\u011bl\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kova\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Manakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pankr\u00e1c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Doln\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pokorn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Etrych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113876_bb0005","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1039\/D2CS00446A","article-title":"Non-internalising antibody-drug conjugates","volume":"51","author":"Ashman","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.113876_bb0010","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2025.113876_bb0015","first-page":"339","article-title":"Antibody-drug conjugates: in search of partners of choice, trends","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.113876_bb0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113876_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/antib9010002","article-title":"Antibody conjugates-recent advances and future innovations","volume":"9","author":"Leung","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2025.113876_bb0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/2472555220912955","article-title":"Advances in antibody\u2013drug conjugate design: current clinical landscape and future innovations","volume":"25","author":"Gauzy-Lazo","year":"2020","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.jconrel.2025.113876_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030626","article-title":"Targeted drug delivery and Theranostic strategies in malignant lymphomas","volume":"14","author":"Etrych","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2025.113876_bb0045","doi-asserted-by":"crossref","first-page":"2100032","DOI":"10.1002\/adfm.202100032","article-title":"Antibody-drug-conjugate therapy for hematological cancers: matching cell biology with clinical benefit","volume":"31","author":"Firer","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113876_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/CCO.0000000000001065","article-title":"Update of antibody-drug conjugates for hematological malignancies","volume":"36","author":"Sun","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160890","article-title":"Structural basis of microtubule destabilization by potent Auristatin anti-Mitotics","volume":"11","author":"Waight","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.113876_bb0070","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","article-title":"Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules","volume":"9","author":"Lopus","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2025.113876_bb0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.113876_bb0080","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.113876_bb0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2017.02.027","article-title":"Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates","volume":"253","author":"Pabst","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113876_bb0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0095","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody\u2013drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.113876_bb0100","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1021\/acs.bioconjchem.8b00252","article-title":"Covalent modification of biomolecules through Maleimide-based labeling strategies","volume":"29","author":"Renault","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.113876_bb0105","first-page":"43","article-title":"Bioconjugation with Maleimides: a useful tool for chemical biology, chemistry \u2013 a","volume":"25","author":"Ravasco","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0110","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1039\/C5PY00168D","article-title":"Thiol\u2013maleimide \u201cclick\u201d chemistry: evaluating the influence of solvent, initiator, and thiol on the reaction mechanism, kinetics, and selectivity","volume":"6","author":"Northrop","year":"2015","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2025.113876_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/bc500610g","article-title":"CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability","volume":"26","author":"Kolodych","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.113876_bb0120","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jconrel.2015.09.032","article-title":"Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides","volume":"220","author":"Christie","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113876_bb0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.113876_bb0130","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1021\/acs.molpharmaceut.5b00432","article-title":"Antibody-drug conjugates (ADCs) derived from Interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs","volume":"12","author":"Behrens","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113876_bb0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2020.06.040","article-title":"HPMA copolymer-antibody constructs in neoplastic treatment: an overview of therapeutics, targeted diagnostics, and drug-free systems","volume":"325","author":"Rand\u00e1rov\u00e1","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113876_bb0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2017.02.034","article-title":"A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas","volume":"103","author":"Zhang","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113876_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2007.06.007","article-title":"Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy","volume":"122","author":"Etrych","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113876_bb0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2020.08.042","article-title":"Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab","volume":"328","author":"Lidick\u00fd","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113876_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113876_bb0160","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as theranostic target in oncology","volume":"22","author":"Valentina","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113876_bb0165","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/10428190902930470","article-title":"Bright CD38 expression is an indicator of MYC rearrangement","volume":"50","author":"Maleki","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2025.113876_bb0170","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1039\/D1PY00707F","article-title":"The role of the biotin linker in polymer antibody mimetics, iBodies, in biochemical assays","volume":"12","author":"\u0160ubr","year":"2021","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2025.113876_bb0175","doi-asserted-by":"crossref","unstructured":"S. Massa, N. Devoogdt, Bioconjugation, 2033 (2019). doi: https:\/\/doi.org\/10.1007\/978-1-4939-9654-4.","DOI":"10.1007\/978-1-4939-9654-4"},{"key":"10.1016\/j.jconrel.2025.113876_bb0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(99)00141-8","article-title":"Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation","volume":"64","author":"Ulbrich","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113876_bb0185","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/macp.1977.021780803","article-title":"Aminolyses of monomeric and polymeric 4-nitrophenyl esters of N-methacryloylamino acids","volume":"178","author":"Rejmanov\u00e1","year":"1977","journal-title":"Die Makromolekulare Chemie"},{"key":"10.1016\/j.jconrel.2025.113876_bb0190","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.reactfunctpolym.2006.05.002","article-title":"Synthesis and properties of new N-(2-hydroxypropyl)methacrylamide copolymers containing thiazolidine-2-thione reactive groups","volume":"66","author":"\u0160ubr","year":"2006","journal-title":"React. Funct. Polym."},{"key":"10.1016\/j.jconrel.2025.113876_bb0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jconrel.2025.113876_bb0200","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/macp.1983.021841006","article-title":"Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B, die","volume":"184","author":"Rejmanov\u00e1","year":"1983","journal-title":"Makromol. Chem."},{"key":"10.1016\/j.jconrel.2025.113876_bb0205","first-page":"1","article-title":"Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors","volume":"11","author":"Daumova","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.113876_bb0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/jpm11020115","article-title":"HPMA copolymer-based nanomedicines in controlled drug delivery","volume":"11","author":"Chytil","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jconrel.2025.113876_bb0215","article-title":"Polymer nanomedicines with enzymatically triggered activation: a comparative study of in vitro and in vivo anti-cancer efficacy related to the spacer structure","volume":"46","author":"Pechar","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.113876_bb0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2018.12.013","article-title":"Phase 2 study of Daratumumab in relapsed\/refractory mantle-cell lymphoma, diffuse large b-cell lymphoma, and follicular lymphoma","volume":"19","author":"Salles","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jconrel.2025.113876_bb0225","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113876_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00749","article-title":"Lysosomal P-gp-MDR1 confers drug resistance of Brentuximab Vedotin and its cytotoxic payload monomethyl Auristatin E in tumor cells","volume":"10","author":"Liu-Kreyche","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113876_bb0235","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.3390\/ijms24108543","article-title":"Old drug, new delivery strategy: MMAE repackaged","volume":"24","author":"Lahnif","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.113876_bb0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.actbio.2020.11.014","article-title":"Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma","volume":"119","author":"Pola","year":"2021","journal-title":"Acta Biomater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:57:02Z","timestamp":1779512222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"alternative-id":["S0168365925004961"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113876","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113876"}}